LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Kostos, Louise [1 ,2 ]
Buteau, James P. [2 ,3 ]
Kong, Grace [2 ,3 ]
Opar, Petra [4 ]
Di Lulio, Juliana [4 ]
Fahey, Michael [4 ]
Fettke, Heidi [2 ,3 ]
Furic, Luc [3 ,5 ]
Hofman, Michael S. [2 ,3 ]
Azad, Arun [2 ,3 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Box Hill, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs39
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [21] Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
    Hofman, Michael S.
    Emmett, Louise
    Sandhu, Shahneen
    Iravani, Amir
    Buteau, James P.
    Joshua, Anthony M.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Ng, Siobhan
    Francis, Roslyn J.
    Gedye, Craig
    Rutherford, Natalie K.
    Weickhardt, Andrew
    Scott, Andrew M.
    Lee, Sze-Ting
    Kwan, Edmond M.
    Azad, Arun A.
    Ramdave, Shakher
    Redfern, Andrew
    Macdonald, William
    Guminski, Alex
    Hsiao, Edward
    Chua, Wei
    Lin, Peter
    Zhang, Alison Yan
    Stockler, Martin R.
    Williams, Scott G.
    Martin, Andrew J.
    Davis, Ian D.
    LANCET ONCOLOGY, 2024, 25 (01): : 99 - 107
  • [22] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Derlin, Thorsten
    Schmuck, Sebastian
    LANCET ONCOLOGY, 2018, 19 (08): : E372 - E372
  • [23] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Anna Yordanova
    Paula Linden
    Stefan Hauser
    Michael Meisenheimer
    Stefan Kürpig
    Georg Feldmann
    Florian C. Gaertner
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080
  • [24] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Meisenheimer, Michael
    Kuerpig, Stefan
    Feldmann, Georg
    Gaertner, Florian C.
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1073 - 1080
  • [25] [177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.
    Vaishampayan, Nitin
    Morris, Michael J.
    Krause, Bernd J.
    Vogelzang, Nicholas J.
    Kendi, Ayse T.
    Nordquist, Luke T.
    Calais, Jeremie
    Nagarajah, James
    Beer, Tomasz M.
    El-Haddad, Ghassan
    Brackman, Marcia
    Desilvio, Michelle
    Messmann, Richard Adam
    Sartor, A. Oliver
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-61 7 versus cabazitaxel
    Lorenz, Kunzell Judith
    AKTUELLE UROLOGIE, 2023, 54 (04) : 269 - 269
  • [27] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Karimzadeh, Amir
    Lehnert, Wencke
    Koehler, Daniel
    Shenas, Farzad
    Kisters, Anna
    Apostolova, Ivayla
    Klutmann, Susanne
    Adam, Gerhard
    Sauer, Markus
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2025,
  • [29] Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
    Tagawa, Scott T.
    Armstrong, Andrew J.
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    De Bono, Johann S.
    Adra, Nabil
    Desilvio, Michelle
    Messmann, Richard
    Holder, Geoffrey
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Sandhu, Shahneen
    LANCET ONCOLOGY, 2018, 19 (08): : E373 - E373
12345